Durvalumab+ Anlotinib + Standard Chemotherapy in First-line Treatment of Extensive Small-cell Lung Cancer: a Single-arm, Single-center, Phase II Clinical Study
Latest Information Update: 15 Jul 2024
At a glance
- Drugs Catequentinib (Primary) ; Durvalumab (Primary) ; Carboplatin; Cisplatin; Etoposide
- Indications Brain metastases; Liver metastases; Small cell lung cancer
- Focus Therapeutic Use
- 04 Jun 2024 Efficacy and safety results (n=22) presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 10 Apr 2022 Planned End Date changed from 4 Nov 2022 to 20 Nov 2023.
- 10 Apr 2022 Planned primary completion date changed from 4 Dec 2021 to 20 May 2023.